Previous close | 4.0000 |
Open | 4.0000 |
Bid | 1.0000 |
Ask | 5.0000 |
Strike | 55.00 |
Expiry date | 2026-01-16 |
Day's range | 4.0000 - 4.0000 |
Contract range | N/A |
Volume | |
Open interest | 25 |
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) just released its quarterly report and things are looking bullish. It was a...
CAMBRIDGE, Mass., May 03, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.